Ágora Proyectos
ServiciosLa EmpresaÁgora DigitalNoticias del Sector

New Era 59fifty Low Crown

New Era 59fifty Low Crown

Biogen Idec's pipeline of products in development includes ANTEGREN(R) (natalizumab), which, in partnership with Elan Corporation plc, is in Phase III clinical studies for the treatment of multiple sclerosis and Crohn's disease; RITUXAN which is in Phase III trials for rheumatoid arthritis and other cancer indications; the second generation oral fumarate, which is in Phase III clinical trials in Europe; and an anti CD23 antibody, which will soon enter Phase II trials for chronic lymphocytic leukemia (CLL).

J. Bucknum, Executive Vice President, General Counsel, and John M. Dunn, Executive Vice President, New Ventures;

New Era 59fifty Low Crown

R employees, including approximately 400 in discovery research; and

New Era 59fifty Low Crown

Thomas Nike Cap Outfit

A strong commitment to pioneering new standards of care through an

New Era 59fifty Low Crown

CAMBRIDGE, Mass., and SAN DIEGO, Nov. 12 /PRNewswire FirstCall/ IDEC Pharmaceuticals Corporation and Biogen, New Era 59fifty Low Crown Inc. The combined company, Biogen Idec Inc., will commence trading on NASDAQ tomorrow under the stock symbol "BIIB."

making Biogen Idec a strategic partner for companies seeking to develop

The company will begin with a balance sheet of more than $1.5 billion in net cash, and a commitment toward delivering on each of the financial goals it has articulated since the merger was announced. The company expects to achieve 15 percent compound annual revenue growth and approximately 20 percent compound annual cash earnings per share growth through 2007, and to generate cumulative operating expense synergies of over $300 million and cumulative capital expenditure synergies of over $175 million through 2007.

excellence in San Diego and Cambridge;

New Era 59fifty Low Crown

drugs, AVONEX(R) (Interferon beta 1a) and RITUXAN(R) (rituximab), and

An aggressive drug development program, with initiatives focused on

New Era 59fifty Low Crown

promising new therapies;

Biogen Idec begins operations with several impressive features, including:

expected annual R budget of more than $550 million and 1,000 dedicated

"We are excited to begin our new life as Biogen Idec and to capitalize on the momentum we have Nike Cap Maroon

10 products in clinical development;

Honorable Lynn Schenk, Phillip A. and William D. Young.

Strong franchises in oncology and immunology, supported by centers of

Japan, Canada, Australia, and New Zealand. A vast network of

generated as individual companies and in our work planning for a unified organization," said William H. "Based on our existing collaboration in oncology, we knew that this combination would be an excellent fit, both operationally and culturally. Yet it still has been gratifying to witness the realization of this vision over the past five months during our integration planning process."

The Board of Directors of Biogen Idec will consist of 12 directors, six from each company, including Mr. Mullen and Dr. Rastetter. Dr. Rastetter will serve as Executive Chairman of the Board of Directors. The 10 non employee Board members are Alan Belzer, Lawrence C. Best, Alan B. Keller, Robert W. Pangia, Bruce R. Ross, the New Era Winter Classic

1 And 3 Complete Merger To Create New Biotechnology Industry Leader Third Largest Biotech Company

Global reach, including operations in 16 European countries, as well as

A diverse product portfolio and revenue base, with two blockbuster

New Era 59fifty Low Crown

distributors sells Biogen Idec products in over 50 countries.

"Since the announcement of our proposed merger in June, our lead products AVONEX and RITUXAN have performed exceptionally well, and we have continued to mark progress in our combined late stage pipeline," said James C. Mullen, Biogen Idec's Chief Executive Officer. "In addition, Biogen Idec will leverage strategic assets including $1.5 billion in net cash and manufacturing expertise and capacity to achieve our goal of in licensing approximately 50 percent of our pipeline by 2010."

New Era 59fifty Low Crown

New Era 59fifty Low Crown

In addition to Dr. Rastetter and Mr. Mullen, Biogen Idec's executive officers are:

New Era 59fifty Low Crown

New Era 59fifty Low Crown

New Era Montreal Expos

Gucci Belt Women Black
Detroit Tigers Cap

Ferragamo Belt Xl Buckle
New Era Denver Broncos

Nike Hat Girls Tumblr

Nike Cap Back

Hermes Constance Belt Buckle
Cleveland Indians Hat

Nike Cap With No Top

Hermes Belts Prices
Adidas Hat Denim

New Era Caps Offering Online

Nike Cap Black And White

Armani Belt Buckle

Home / New Era 59fifty Low Crown